Istituto Oncologico Veneto IRCCS

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Nov 5, 2026

Completed

Regorafenib in Combination With Temozolomide With or Without Radiotherapy in Patients With Newly Diagnosed MGMT-Methylated, IDH Wild-type Glioblastoma. A Phase I Dose-finding Study

Nov 5, 2026

Recruiting

Scarless Advanced Breast Extended Oncoplasty: The ScarABEO Study

Earlier

Oct 3, 2026TrialSilibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients: a Multicenter, Double-blind, Placebo-controlled, Randomized Study

Oct 1, 2026TrialRegorafenib for Recurrent Meningioma. A Multicenter, Randomized Phase II Study (MIRAGE Trial)

Sep 26, 2026TrialFrom Immune Microenvironment Characterization and Gene Expression Profiling to New Drugs Testing in Pleural and Peritoneal Mesothelioma: Imaging-Meso Study

Sep 24, 2026TrialIntraOperative UltraSound Guided Versus Wire Guided Versus Magnetic Seed Guided Breast-conserving Surgery for Non-palpable Tumors.The MANOLA Study Multi-center, Randomized, Open-label Clinical Trial

Sep 3, 2026TrialNAPOLI: Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study

Aug 7, 2026TrialIdentification of Targetable Vulnerabilities in Redox Homeostasis Pathways as a Novel Therapeutic Approach for Human T-cell Malignancies

2 more events

Aug 5, 2026TrialA Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer

Aug 5, 2026TrialL'Utilizzo Della realtà Virtuale Mediante l'Impiego Del Visore Ottico Nel Paziente Oncologico Sottoposto al Posizionamento di PICC e PICC-PORT

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)